drugset / Trial / NCT02703584

Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation

NCT02703584

Phase 4 Completed 276 enrolled Mount Sinai Hospital, Canada
RandomizedParallel-groupQuadruple-blindTreatment

Summary

All the studies, demonstrating improved oocyte maturity and high pregnancy rate with the dual trigger are all retrospective. The investigators therefore aim to perform a prospective randomized controlled study in normal responders, comparing cycles triggered with hCG to those triggered with hCG+GnRH agonist.

Timeline

Start
2016-03
Primary completion
2018-09
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Subject suprefact Unknown 0.5 mg
Background human chorionic gonadotropin Protein / enzyme biologic 10000 iu

Indications